These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 18053638

  • 1. Cytochrome P450s in the development of target-based anticancer drugs.
    Purnapatre K, Khattar SK, Saini KS.
    Cancer Lett; 2008 Jan 18; 259(1):1-15. PubMed ID: 18053638
    [Abstract] [Full Text] [Related]

  • 2. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A, Komorowski J, Wikberg JE.
    J Chem Inf Model; 2008 Sep 18; 48(9):1840-50. PubMed ID: 18693719
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C, Ingelman-Sundberg M.
    Oncogene; 2006 Mar 13; 25(11):1679-91. PubMed ID: 16550168
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
    Kumar G, Lau H, Laskin O.
    Cancer Chemother Pharmacol; 2009 May 13; 63(6):1171-5. PubMed ID: 19030860
    [Abstract] [Full Text] [Related]

  • 7. Cytochromes P450 and drug discovery.
    Lamb DC, Waterman MR, Kelly SL, Guengerich FP.
    Curr Opin Biotechnol; 2007 Dec 13; 18(6):504-12. PubMed ID: 18006294
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications.
    Zhang YY, Yang L.
    Expert Opin Drug Metab Toxicol; 2009 Jun 13; 5(6):621-9. PubMed ID: 19473111
    [Abstract] [Full Text] [Related]

  • 12. Drug interactions of H2-receptor antagonists involving cytochrome P450 (CYPs) enzymes: from the laboratory to the clinic.
    Rendić S.
    Croat Med J; 1999 Sep 13; 40(3):357-67. PubMed ID: 10411963
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery.
    Bell L, Bickford S, Nguyen PH, Wang J, He T, Zhang B, Friche Y, Zimmerlin A, Urban L, Bojanic D.
    J Biomol Screen; 2008 Jun 13; 13(5):343-53. PubMed ID: 18474896
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism.
    Muruganandan S, Sinal CJ.
    Clin Pharmacol Ther; 2008 Jun 13; 83(6):818-28. PubMed ID: 18388875
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues.
    Appiah-Opong R, de Esch I, Commandeur JN, Andarini M, Vermeulen NP.
    Eur J Med Chem; 2008 Aug 13; 43(8):1621-31. PubMed ID: 18249473
    [Abstract] [Full Text] [Related]

  • 20. [Role of cytochrome P450 enzymes in pharmaceutical preparations].
    Baede van Dijk PA, de Graeff PA, Lekkerkerker JF.
    Ned Tijdschr Geneeskd; 1999 Dec 25; 143(52):2607-11. PubMed ID: 10633805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.